Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

Autor:	Tina M. Schnöder, Florian Perner, Stephanie Frey, Denise Wolleschak, Marie-Christine Wagner, Burkhart Schraven, Monika C. Brunner-Weinzierl, Thomas S. Mack, Berend Isermann, Stefanie Kliche, Christine Höding, Thomas Fischer, Andreas Parkner, Satish Ranjan, Florian H. Heidel, Daniel B. Lipka, Marina C. Pils, Katrin Hebel
Jazyk:	angličtina
Rok vydání:	2014
Předmět:	Kinase Phenylurea Compounds T-Lymphocytes Myeloid leukemia Hematology Biology Staurosporine Discontinuation chemistry.chemical_compound chemistry fms-Like Tyrosine Kinase 3 hemic and lymphatic diseases Immunology Fms-Like Tyrosine Kinase 3 Cancer research medicine Humans Midostaurin Benzothiazoles Stem cell Online Only Articles Quizartinib medicine.drug
Popis:	The vast majority of acute myeloid leukemia (AML) patients harboring an FLT3-ITD mutation experience relapse within a short period of time after discontinuation of chemotherapy.[1][1] Treatment options include experimental trials using FLT3-tyrosine kinase inhibitors (TKI) or allogeneic stem cell
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f37b908def101aef3ed490489ee527b https://hdl.handle.net/10033/325037 Zobrazit plný text záznamu